Form 4: Corcept Therapeutics Director James N. Wilson Acquires 80,000 Stock Options
SEC Form 4 Filing
Director James N. Wilson of Corcept Therapeutics acquired 80,000 employee stock options on May 17, 2024.
Summary
- On May 17, 2024, James N. Wilson, a director of Corcept Therapeutics, acquired 80,000 employee stock options.
- The exercise price of these options is $28.09.
- The options vest ratably in equal monthly installments over a one-year period, starting May 17, 2024.
- The options expire on May 16, 2034.
- Following the transaction, Wilson directly owns 80,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a standard stock option grant, with no inherent positive or negative implications.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of management with shareholders.
Stakeholder Impact
- The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | Date of the transaction: James N. Wilson acquired 80,000 employee stock options. |
| 05/17/2024 | First exercisable date: Options vest ratably in equal installments on each monthly anniversary of this date over a one-year period. |
| 05/16/2034 | Expiration date of the employee stock options. |
| 05/21/2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.